xrimatistirio.com
Lavipharm logo
LAVIΥγεία · Φάρμακα · ΧΑ

Lavipharm

1,590
-0,01(-0,50%)
Κλείσιμο 10/09/2026 · τιμή τέλους ημέρας, όχι σε πραγματικό χρόνο
Η άποψή μου
Ιδιωτικό · ο MENTOR το λαμβάνει υπόψη
10/09/2026Κ 1,590-0,008 -0,50%Όγκος 29,3χιλ.
Η εταιρεία

Lavipharm S.A. is a Greek pharmaceutical company engaged in the development, production, and distribution of prescription drugs, over-the-counter medicines, cosmetics, and health products. As a leader in the pharmaceutical and healthcare sectors in Greece, Lavipharm is committed to innovation and quality in its various offerings. The company’s portfolio addresses a wide array of therapeutic areas, including dermatology, cardiology, and central nervous system disorders, reflecting its diverse approach in catering to comprehensive health and wellness needs. Founded in 1911, Lavipharm has grown to play a pivotal role in pharmaceutical distribution and marketing across Greece, with a strong focus on manufacturing practices and research and development initiatives. The company's strategic collaborations and partnerships with international firms further bolster its market reach and expertise. Lavipharm's operations also extend into areas of transdermal drug delivery systems, showcasing its emphasis on cutting-edge healthcare solutions. As a significant player in the Greek pharmaceutical industry, Lavipharm continues to contribute to the advancement of medical care and pharmaceutical innovations.

Αποτίμηση
ΜέγεθοςLAVIΔιάμεσος 2 ομοειδών
P/E54,058,6
P/B4,90,98
P/S4,30,59
EV/EBITDA22,69,0
Μερισμ. απόδοση0,0%0,0%
Διανομή κερδών68,5%
Λειτουργικό περιθώριο12,5%7,1%
Καθαρό περιθώριο8,0%4,0%
ROE10,6%2,4%
Αύξηση εσόδων (τρίμηνο, ετήσια)15,4%1,1%
Καθαρός δανεισμός26,7εκ. €74,7εκ. €
Στοιχεία Twelve Data · τελευταίο τρίμηνο 31/12/2025
Στον ίδιο κλάδο: Υγεία
P/SΗμέρα
LavipharmLAVI4,3-0,5%
Athens Medical CenterIATR0,50+0,0%Medicon HellasMEDIC0,68-2,9%
Δεύτερο μέγεθος: Αύξηση εσόδων: LAVI 15,4% · IATR 3,8% · MEDIC 6,0%
MENTORΔωρεάν beta
Δεδομένα: Twelve Data · Τιμές τέλους ημέρας · Δεν αποτελεί επενδυτική συμβουλή.